RBC Capital on Provention Bio Inc. (PRVB): 'we believe an approval has already been priced in and we watch for the durability of share levels'
Tweet Send to a Friend
RBC Capital analyst Gregory Renza reiterated a Sector Perform rating and $9.00 price target on Provention Bio Inc. (NASDAQ: PRVB)The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
